In today’s research environment, transparency is no longer something sponsors aspire to, it's an operational expectation shared by regulators, patients, and the broader scientific community. The demand is clear: clinical trial data must be accessible, useful, and responsibly shared. Yet for many sponsors, meeting these expectations is anything but straightforward.

The challenge lies in balancing two equally important goals:

• Openness, to strengthen scientific integrity and public trust; and
  
• Protection, to safeguard participant privacy, intellectual property (IP), and confidential business information.
  

Unfortunately, most organizations still navigate transparency requirements through disconnected processes that were never designed to work together. Redaction, anonymization, and CI classification often happen in separate systems, by separate teams, on separate timelines. The results are predictable, gaps, inconsistencies, delays, and elevated regulatory risk.

A more sustainable and defensible model is emerging: a single integrated workflow that connects all transparency tasks under one operational framework. This approach allows sponsors to meet their legal and ethical obligations without sacrificing efficiency or exposing sensitive information.

The Problem: Fragmented Workflows Create Avoidable Risk

Over the past decade, sponsors have made major progress in expanding access to clinical trial information. Yet even organizations with mature disclosure functions often struggle with the operational reality behind the scenes. Common issues include:

1. Inconsistent Standards Across Teams

When redaction and anonymization are executed by different groups, sometimes even by different external vendors, each may apply its own interpretation of regulatory requirements. This creates variability across submissions, which raises red flags with regulators and can undermine defensibility.

2. Manual, Siloed Approaches

Despite the complexity of clinical documentation, many transparency tasks are still managed using spreadsheets, email chains, and manually applied redaction tools. These ad hoc methods increase the likelihood of human error and make it difficult to maintain version control or demonstrate compliance during audits.

3. Over-Redaction and Under-Redaction

Excessive redaction can strip documents of scientific value. Insufficient redaction can expose personal data or proprietary information. Fragmented workflows make it harder to strike the right balance, putting both regulatory relationships and competitive advantage at risk.

4. Reactive Confidential Information Management

Confidential information is often identified too late in the submission process, sometimes only after documents have already been shared with external teams. This reactive approach increases the chance of accidental disclosure of trade secrets, strategic plans, and competitive intelligence.

Each of these challenges introduces operational friction and regulatory exposure. Together, they create an environment where transparency efforts become slower, more expensive, and less defensible than they need to be.

The Solution: A Unified, Technology-Enabled Workflow

A modern approach to clinical trial transparency brings all critical components, document redaction, quantitative anonymization, and confidential information governance into a single integrated workflow. This not only increases efficiency but ensures every action is traceable, consistent, and aligned with regulatory expectations.

The unified model rests on three essential pillars:

Pillar 1: Standardized Document Redaction

Document redaction is still the backbone of most transparency processes, but it is often applied in inconsistent or subjective ways. A unified workflow brings structure and standardization to the process by:

• Defining clear rules for what constitutes personal data, sensitive operational content, and confidential business information.
  
• Applying redactions consistently across all documents and submissions.
  
• Ensuring records of every redaction are captured for audit readiness.
  

With standardized criteria and built-in review mechanisms, sponsors can avoid both over-redaction (which reduces clinical utility) and under-redaction (which exposes them to compliance risk).

Pillar 2: Quantitative (Risk-Based) Anonymization

Regulators increasingly expect sponsors to use measurable, risk-based techniques for protecting participant privacy. Qualitative judgments alone are no longer sufficient.

By integrating quantitative anonymization into the workflow, sponsors can:

• Use statistical models to evaluate re-identification risk.
  
• Apply anonymization methods that are tailored to data types and participant populations.
  
• Demonstrate compliance through documented risk assessments.
  

Embedding anonymization into the process—not bolting it on at the end—ensures that shared data remains both scientifically meaningful and privacy-protected.

Pillar 3: Centralized Confidential Information Governance

Confidential information governance is often the most overlooked aspect of transparency. Sponsors must protect strategy, innovation, and competitive insights without impeding disclosure obligations.

A unified workflow strengthens CI governance by:

• Creating a centralized catalog of CI categories and rules.
  
• Applying consistent criteria for classification and protection.
  
• Capturing electronic audit trails for every CI decision.
  
• Ensuring cross-functional review by clinical, regulatory, legal, and IP stakeholders.
  

When CI governance is built into the workflow rather than handled as an afterthought, sponsors gain stronger defensibility and avoid costly accidental disclosures.

What an Integrated Workflow Should Deliver

A unified transparency workflow is more than a new set of tools, it is an operational framework. The most effective systems provide:

1. A Centralized, Living Repository

A single source of truth containing CI rules, risk thresholds, redaction standards, and historical decisions.

2. Built-In Collaboration

Role-based access, shared workspaces, and structured review cycles engage all relevant stakeholders.

3. End-to-End Auditability

Every redaction, anonymization step, and CI designation is logged, timestamped, and reviewable.

4. Regulatory Alignment Across Regions

Consistent workflows that can stand up to scrutiny from EMA, Health Canada, FDA, and other global regulators.

5. Repeatability and Scalability

Standardized processes reduce rework, shorten submission timelines, and help teams handle larger volumes of transparency activities.

This integrated model transforms transparency from a compliance burden into a streamlined, reliable operational capability.

The Benefits for Sponsors

Organizations that adopt unified workflows experience tangible improvements:

Greater Consistency

Standardized rules reduce variability across teams, therapeutic areas, and studies.

Enhanced Compliance

Traceable, risk-based decisions align more closely with regulatory expectations and audit requirements.

Improved Trust and Credibility

Regulators, partners, and participants have greater confidence in the sponsor’s transparency practices.

Operational Efficiency

Eliminating redundant reviews and manual steps reduces timelines and resource strain.

Stronger Protection for Both Privacy and IP

A structured approach shields participant identities and proprietary information without compromising data value.

Looking Forward: A Future Where Transparency Is Seamless

Clinical trial transparency is poised to become even more integral to research operations as regulatory expectations grow and participants demand greater visibility into how their data is used. The organizations best positioned to succeed will be those that treat transparency not as a compliance “checkbox” but as a strategic capability.

A unified workflow represents a shift toward:

• Proactive risk management
  
• Cross-functional collaboration
  
• Technology-driven consistency
  
• Defensible and auditable decision-making
  

Sponsors who embrace this model can meet rising expectations with confidence—while protecting what matters most.

Conclusion: One Workflow, Many Advantages

The future of clinical trial transparency depends on moving beyond manual, fragmented processes. By bringing redaction, quantitative anonymization, and CI governance together in a single, unified workflow, sponsors can achieve a powerful combination of consistency, efficiency, and defensibility.

This integrated model isn’t theoretical, it’s available today. Industry leaders are already leveraging technology-enabled workflows to protect participant data, streamline disclosure tasks, and manage confidential information in a structured, repeatable way.

If you’re exploring how to modernize your transparency strategy, organizations like Real Life Sciences offer resources and perspectives on scaling CI governance, risk-based anonymization, and SaaS-enabled redaction workflows. With the right framework in place, sponsors can transform a once-fragmented process into a reliable, compliant, and trusted transparency program.

In the evolving landscape of clinical research, data privacy, compliance, and transparency are more critical than ever. Regulatory agencies around the world—such as the EMA, Health Canada, and the FDA—are demanding higher levels of transparency in clinical trial documentation while simultaneously holding sponsors accountable for protecting sensitive Confidential Information (CI), including trade secrets and intellectual property (IP).

This dual mandate has created a paradox for life sciences organizations: How can companies be transparent without compromising confidentiality and protection of its trade secrets and IP? The answer lies in technology—and more specifically, in RLS Protect Confidential Information Management (CIM), a groundbreaking platform developed by Real Life Sciences (RLS). CIM is redefining how pharmaceutical companies and contract research organizations (CROs) identify, review, approve, and manage confidential information across the clinical trial lifecycle.

The Compliance Challenge in Clinical Trials

The regulatory landscape surrounding clinical data disclosure has grown increasingly complex. Regulations such as EU Clinical Trial Regulation (CTR), EMA Policy 0070 and Health Canada’s Public Release of Clinical Information guidance require that sponsors disclose vast amounts of clinical data for public review. However, this disclosure must be executed with extreme caution—companies must carefully redact personal data, proprietary processes, compound names, and other CI that, if released, could harm competitive advantage or violate privacy laws such as GDPR.

Traditional redaction processes are manual, time-consuming, error-prone, and often lack cross-functional transparency. As documents pass between regulatory, legal, medical writing, and data privacy teams, the risk of inconsistency or misclassification increases—leading to compliance gaps, costly rework, or even worse - premature release of confidential information or public relations nightmares.

That’s where RLS Protect CIM comes in.

What Is RLS Protect CIM?

RLS Protect CIM is a web-based Software as a Service (SaaS) platform that provides pharmaceutical manufacturers with end-to-end management and visibility of confidential information . Designed specifically for clinical trials, CIM, in combination with RLS Protect for document redaction, is a centralized, collaborative system that enables teams to:

• Identify and categorize confidential information (CI)
  
• Route CI for multi-stakeholder review and approval
  
• Track and verify CI across documents and public domains
  
• Automatically flag and redact approved CI identified within documents intended for publication
  

CIM transforms confidential information management from a reactive, manual process into a proactive, intelligent workflow supported by real-time collaboration and machine learning.

Why CIM Is Crucial in Today’s Regulatory Environment

1. Protects Intellectual Property and Competitive Advantage

At its core, CIM helps sponsors protect what matters most— proprietary data, novel compounds, and strategic insights. By systematically managing CI through a structured workflow, sponsors reduce the risk of accidental disclosure of trade secrets, compound codes, or proprietary formulations.

With CIM, organizations can build a CI library tied to specific assets (such as investigational drugs or molecules), classify each CI by category, and define justifications for protection. This ensures CI is tracked consistently across projects and documents.

2. Enables Proactive Risk Management

CIM doesn’t just manage known CI—it actively scans the public domain for potential matches, alerting stakeholders if confidential information appears to have been previously disclosed. This feature is invaluable for monitoring data leakage and responding quickly if proprietary data becomes public outside the approved process

CIM also integrates directly with RLS Protect Docs, allowing users to auto-load CI annotations into redaction workflows. This means that any CI flagged in CIM will automatically be suggested for redaction while preparing documents for publication—streamlining compliance and reducing human error.

3. Drives Regulatory Readiness and Auditability

CIM provides a full audit trail of every CI item, capturing who in the organization processed it, when it was reviewed or approved (and by whom), and any changes to its classification. This traceability is essential during regulatory audits and inspections and for standardizing and tracking confidential information internally in real time.

The system also enables different user roles—such as Admin, CIM Manager, Reviewer, and Approver—ensuring that only authorized individuals perform specific actions. Workflow statuses like “Draft,” “Submitted for Review,” “In Approval,” and “Approved” provide transparency into where each CI item stands in the review lifecycle.

This level of governance is not just best practice—it’s increasingly becoming the norm for organizations seeking to improve visibility and control around confidential information for their enterprise.

4. Reduces Cross-Functional Confusion and Bottlenecks

One of the biggest pain points in document disclosure and redaction projects is the seemingly endless back-and-forth between teams. Different departments have different definitions of what constitutes CI, leading to inconsistent decisions, delayed timelines, and frustration. These perspectives may or may not align to that of the Health Authority.

CIM solves this by centralizing CI decision-making. Once a CI is reviewed and approved within CIM, that decision is codified across the entire organization. Any redaction specialist, legal resource, or regulatory lead reviewing a document knows exactly what to redact—because the approved CI is already captured in the system..

Fewer meetings. Fewer errors. Faster submissions and document review cycles..

5. Enables Scalable Redaction Across Projects

With clinical development pipelines expanding, legal requests multiplying and global submissions becoming the norm, sponsors must manage redaction efforts across hundreds of studies and thousands of documents. Manual systems simply don’t scale.

CIM is designed for scale. It allows users to link CI to specific projects, track National Clinical Trial (NCT) numbers and other registry identifiers, and provide real-time visibility to all pending and approvedt CI data across teams. New CI can also be added from within the fully integrated RLS Protect Docs module while redacting, ensuring nothing is missed—even in fast-paced, high-volume environments.

6. Advanced Machine Learning and NLP

While traditional redaction is purely manual, CIM enhances automation through innovative and verified technologies like Natural Language Processing (NLP) and Machine Learning (ML). These features proactively identify likely CI candidates in documents based on trained models.

This intelligent layer adds speed and consistency while freeing up subject matter experts to focus on the most sensitive decisions.

Integrated, Secure, and User-Centric

CIM requires no local installation and is accessible via any supported web browser. Hosted and maintained by RLS, it includes technical support, routine updates, and minimal downtime thanks to off-hours release schedules. RLS maintains a robust Information Security Management System and ISO 27001 certificate to ensure your data is safe and secure at all times.

It also offers robust filtering, exporting, and role-based permission controls, allowing organizations to tailor usage to their structure, roles and responsibilities. Whether you’re a multinational pharma company or a nimble biotech, CIM is designed to adapt to your needs.

A Must-Have for Modern Disclosure and Legal Teams

In today’s clinical trials regulatory environment, maintaining control over confidential information is no longer optional—it’s a critical success factor. Transparency and disclosure obligations will only increase, and companies that fail to manage CI effectively risk reputational damage, regulatory penalties, or worse: loss of competitive edge.

RLS Protect CIM empowers teams to face these challenges with confidence. It combines rigorous compliance with operational efficiency, helping sponsors safeguard their IP, streamline workflows, and meet global transparency requirements.

For any life sciences organization serious about disclosure readiness, consistency and protecting company IP, RLS Protect CIM is not just a tool—it’s a strategic imperative.

Don’t let confidentiality gaps delay your submissions or put your IP at risk. Contact Real Life Sciences today to learn how RLS Protect CIM ensures regulatory compliance—efficiently and at scale

As the demand for expanded transparency in clinical research grows, pharmaceutical and biotechnology companies face increasing pressure to disclose detailed clinical trial information. Regulatory policies such as the European Medicines Agency's (EMA) Policy 0070 and Health Canada's Public Release of Clinical Information (PRCI) initiative exemplify a shift toward openness.

While transparency enhances public trust, fosters scientific innovation, and supports informed decision-making by healthcare professionals and patients, it also introduces a significant challenge: how to share clinical data and related contextual information without compromising a company’s confidential information (CI).

Confidential Information (CI) refers to a company’s proprietary or commercially sensitive information—not patient-level data. While clinical trial transparency initiatives like EMA Policy 0070 and Health Canada’s PRCI aim to make clinical results accessible to the public, they still recognize the need to protect certain types of information that could impact a sponsor’s competitive position. CI typically includes details such as manufacturing processes, product formulations, exploratory endpoints, or strategic development plans. It is distinct from patient data, which is handled separately under data anonymization requirements to protect individual privacy and mitigate the risk of re-identiification. Understanding this distinction is critical for organizations to properly manage disclosures while safeguarding their intellectual property.

This blog explores the complexities of managing CI in a global disclosure environment and outlines practical strategies companies can adopt to meet these transparency mandates without exposing sensitive information.

The Regulatory Landscape: EMA CTR, Policy 0070 and Health Canada PRCI

The European Medicines Agency’s Clinical Trials Regulation (CTR), which became  effective in January 2022, introduced a centralized system for submitting and publishing clinical trial data via the Clinical Trials Information System (CTIS). Under CTR, sponsors are required to register trials and submit key documents such as protocols, patient facing documents (ICFs), and specific and recruitment documents, many of which become publicly accessible. While the regulation allows for the redaction of Confidential Information (CI) the window for justifiable redactions is narrower and publication is bound by strict timelines.

EMA Policy 0070 governs the proactive publication of clinical data submitted in support of Marketing Authorisation Applications (MAAs) in the European Union. This includes clinical study reports (CSRs), protocols, statistical analysis plans, and other key documents. While the policy allows companies to redact CI, it requires that redactions be proposed early—ideally before the submission—and be thoroughly justified.

Health Canada's PRCI initiative similarly promotes the release of clinical information for drugs and medical devices authorized for sale. Sponsors may request redactions to protect CI, but these requests must be well-supported, and final approval rests with the regulator.

Both policies aim to promote transparency while protecting proprietary interests—but the balance between these goals is not always straightforward.

The Complexities of Managing Confidential Information

The identification, justification, and redaction of CI within clinical trial documents is a multifaceted challenge. It requires alignment across internal teams, a deep understanding of what qualifies as CI under various regulations, and proactive planning. Here are five common challenges companies face—and strategies to overcome them.

1. Confidential Information Must Be Identified Throughout the Clinical Lifecycle to Protect IP

One of the most significant difficulties is the requirement to identify and justify CI early in the process - at the time of clinical trial application. Many organizations begin the process only after receiving regulatory prompts or when public disclosure submissions are due, which can lead to rushed decisions and increased risk of rejection.

Solution: Start planning for CI redactions prior to initiating a trial. Develop a proactive workflow that includes early identification of sensitive information, cross-functional input, and documentation of justifications. This should include representation from IP Legal, Regulatory, Safety, Clinical Development teams and Clinical Disclosure. Consider integrating this process into regulatory strategy discussions at the outset of trial planning. This is particularly critical under the EU Clinical Trials Regulation (CTR), where the Clinical Trials Information System (CTIS) generates public versions of submitted documents—such as protocols and investigator brochures—soon after submission of application documents. Without early CI planning, sponsors may lose the opportunity to adequately protect proprietary content before these documents are made publicly available which can lead to unintentional disclosure and downstream IP protection risks.

2. Unclear Ownership and Decision-Making

Managing CI often involves input from multiple functions—regulatory affairs, clinical operations, legal, medical writing, and commercial teams. Without a clearly defined ownership model, decision-making becomes slow, inconsistent, and contentious.

Solution: Establish a clear governance structure using a RACI (Responsible, Accountable, Consulted, Informed) model. Assign roles for CI reviewers, approvers, and escalation contacts. Standardize decision-making criteria through documented SOPs and ensure consistency across projects and geographies.

3. Reactive and Ad-Hoc Identification Processes

All too often, CI redaction is treated as a last-minute task, executed just before submission deadlines. This reactive approach increases the risk of inconsistencies, rework, and missed opportunities to protect proprietary data.

Solution: Implement a standardized CI log or tracking system for each clinical development program. Use templates to flag common types of sensitive content and refine over time based on regulatory feedback. Pair this with regular internal training to raise awareness of CI boundaries.

4. Inconsistencies Across Disclosed Documents and Projects

Different teams or affiliates may make inconsistent redaction decisions for similar types of information. For example, product specifications or exploratory endpoints might be redacted in one submission but disclosed in another.

Solution: Use central repositories to document past decisions and build institutional knowledge. Designate a CI lead to ensure consistency across submissions. Adopt harmonized SOPs that specify criteria for redaction, and conduct quality control reviews to ensure alignment.

5. Managing Regulatory Questions and Requests for Information (RFIs)

Regulators frequently issue RFIs when they consider redactions to be overly broad or insufficiently justified. Full-paragraph or full-page redactions, in particular, tend to attract scrutiny. Responding to RFIs can be disruptive and delay approvals.

Solution: Avoid blanket redactions. Instead, redact the minimum necessary content and provide targeted justifications with references to publicly available information or scientific literature. Prepare an RFI response process in advance, including escalation paths and review timelines.

Practical Strategies to Streamline Confidential Information Management

With regulatory expectations becoming more stringent, companies must elevate CI management from an operational task to a strategic function. Below are several practical actions organizations can take:

Standardize Internal Guidance

Develop and maintain a company-wide policy on CI, including clearly defined redaction criteria, examples, and a glossary of commonly redacted terms. These standards should be incorporated into training and embedded in SOPs.

Build a CI Justification Library

Create a central repository of redaction examples, along with the rationale accepted or rejected by regulators. This will help teams avoid reinventing the wheel and allow for faster, more defensible decisions.

Use Technology to Assist Redaction

Invest in tools that can scan documents for potential CI and flag high-risk sections. While final decisions must be made by experts, AI and machine learning solutions can improve consistency and reduce manual effort.

Align Global Disclosure Practices

Different jurisdictions have different standards, but harmonization is possible. Use a core global strategy that accommodates both EMA Policy 0070 and Health Canada PRCI, with localized adaptations where necessary.

Train Early, Train Often

CI awareness should not be confined to disclosure teams. Train clinical teams, medical writers, and project managers so they understand what information is considered sensitive and why. Early awareness can reduce downstream rework.

Preparing for the Future

Transparency requirements are evolving. The re-launch of Policy 0070, upcoming rule changes under the EU Clinical Trials Regulation (CTR), and increasing global alignment on disclosure standards all point to greater scrutiny and earlier demands for disclosure-readiness.

To stay ahead:

• Begin planning for transparency at the study design phase.
  
• Map all clinical trials that may require redaction, including legacy trials.
  
• Review your organizational capacity to respond to new and updated policies.
  
• Engage with regulators proactively to align on expectations.
  

Conclusion

The management of confidential information in the context of clinical trial transparency is a balancing act. Companies must protect their intellectual property while fulfilling obligations to regulators and the public. This requires early planning, cross-functional coordination, clear ownership, and standardized processes.

By embedding CI governance into the broader regulatory and clinical development frameworks, organizations can not only meet compliance requirements but also contribute to the global movement toward greater scientific openness—without sacrificing their competitive edge.

Need help navigating CI challenges? The team at Real Life Sciences has supported dozens of sponsors through EMA CTR/CTIS, Policy 0070 and Health Canada PRCI projects. Reach out for guidance, tools, or hands-on support to streamline your disclosure workflows.
Discover Real Life Sciences breakthrough Confidential Information Management solution.  Protect your confidential information. Simplify compliance.  RLS CIM

The landscape of pharmaceutical transparency is rapidly evolving — and Policy 0070 Step 2 marks a critical milestone. As transparency and data sharing become strategic priorities across the industry, mastering the nuances of Policy 0070 is essential for sponsors, transparency teams and regulatory professionals alike.

Expanding Scope of Policy 0070

Policy 0070 Step 2 broadens the scope of submissions subject to transparency requirements. Unlike previous phases, Step 2 now covers:

• All new marketing authorizations (including those resulting in negative opinions)
  
• Withdrawn applications
  
• COVID-related submissions
  
• Line extensions (new Step 2 inclusion)
  
• Type II variations, including extensions of indications (new Step 2 inclusion)
  

Notably, biosimilar applications, generics, and hybrid submissions remain out of scope.

Smart Authoring: A Game-Changer for Anonymization

One of the most impactful strategies highlighted in recent discussions is smart authoring — a proactive approach that streamlines anonymization by design. A sampling of key practices include:

Consistency in Nomenclature and Formatting

• Standardize date formats across all documents.
  
• Implement uniform participant identification methods.
  
• Maintain consistent terminology and document structure.
  

Reducing Redundancy

• Avoid unnecessary repetition of participant identifiers.
  
• Eliminate clinically irrelevant information.
  
• Focus solely on essential clinical data.
  

Precision in Documentation

• Include only clinically meaningful information.
  
• Align closely with CTD (Common Technical Document) structure standards.
  
• Remove extraneous details that do not support clinical understanding.
  

By embedding smart authoring practices early with your Medical Writing team(s), Transparency and Regulatory teams can significantly reduce downstream anonymization efforts — and streamline the disclosure submission process while reducing regulatory risk.

Anonymization Reports: Precision Matters

The Anonymization Report is a critical piece of any Policy 0070 submission. To reduce the likelihood of questions or requested revisions from Regulators, consider the following when drafting your Anonymization Report:

• Provide detailed documentation outlining what was retained versus what was anonymized or redacted. For example, when addressing an indirect identifier like Medical History, clearly describe your approach. An example would be: Retained all medical history relevant to the study trial indication and redacted all participant medical history unrelated to the study or indication.
• If multiple methods were used, indicate which method was applied to each study and explain the rationale for using more than one method and describe the anonymization techniques in the following sections per each method.
• Clearly report how you gathered your reference population. Select the option from the dropdown that best describes your approach, and provide additional details, including the exact numbers for both the study and reference population.
• Clear documentation of retained versus anonymized and redacted information.
  
• Detailed methodological explanations for anonymization techniques.
  
• Specific reference population numbers and contextual information.
  
• Thorough justification for all anonymization approaches.
  

Transparency in methodology directly impacts regulator trust and reduces the likelihood of feedback cycles or rework.

Confidential Commercial Information (CCI): Justifying Redactions

When submitting a Policy 0070 package there should not be a high volume of Confidential Information (CI) to redact, however, it is important to check carefully and protect the Intellectual Property of the business by redacting when it fits the required criteria. Submitting CCI redactions deserves a strategic and detailed approach:

Understand the Regulatory Framework

• Study EMA’s Annex 3 guidance carefully.
  
• Develop internal CCI evaluation checklists. Contact Real Life Sciences if you need  a template
• To avoid pushback from the Regulator verify what is truly confidential information vs information already in the public domain.
  

Frame Competitive Risks Clearly

• Illustrate with detail how disclosure could confer competitive advantage.
  
• Provide concrete examples of potential commercial harm.
  
• Be specific and evidence-driven when justifying redactions.
  

Pre-Submission Interactions: Why They Matter

Although Pre-Submission Meetings are optional, they are encouraged, especially for sponsors embarking on their first Policy 0070 submission project. We suggest that sponsors:

• Schedule early engagement with the EMA.
  
• Prepare sample documents for preliminary feedback.
  
• Use these interactions to align the proposed anonymization strategy and approach to redacting CCI  with EMA.
  
• Address potential challenges proactively, before submission.
  

If you choose not to hold a Pre-Submission Meeting with EMA then consider sharing your anonymization approach and methodology for key variables, your approach to redacting Commercially Confidential Information and attaching a draft, sample document(s) and working draft of the anonymization report for EMA to review and reply with their comments. This will help to confirm the support of EMA regarding your submission approach as early in the process as possible, thereby avoiding potential rework upon receipt of Proposal Document Package feedback. 

Regardless of which approach you choose, early collaboration can help mitigate surprises after submission of the Proposal Document Package. 

Practical Recommendations for Success

Plan Early

• Start preparations well in advance, especially for those submitting a Policy 0070 package for the first time.
• Foster close collaboration between medical writing and transparency teams.
• Engage an expert. Real Life Sciences is solely focused on providing technology and services to deliver Policy 0070 anonymization projects on-time and on-quality.
  

Looking Ahead

Policy 0070 Step 2 raises the bar for regulatory transparency. Success will depend on early planning, strong cross-functional coordination, and clear documentation (think Anonymization Report and CCI Justification Tables). Companies that start smart authoring early, prepare anonymization strategies alongside clinical writing, track CCI effectively and engage regulators proactively will be better positioned to meet requirements efficiently.

Key next steps for sponsors:

• Develop internal templates for anonymization reports.
  
• Build CCI justification libraries and implement a solution to manage the review, approval and public data verification
  
• Conduct internal training sessions focused on Policy 0070 expectations.
  
• Create cross-functional review teams including clinical, regulatory, and legal experts.
  

Conclusion

Policy 0070 Step 2 is not just about compliance — it's about building an efficient and sustainable process for clinical transparency across regulatory submissions. Teams that prioritize thoughtful authoring, early anonymization planning, and proactive regulator communication will simplify submissions and minimize review risk.

A disciplined approach now will save significant time and resources later — and position teams for success as global transparency expectations continue to evolve.

To learn more about staying ahead of clinical trial transparency submission timelines. Visit rlsciences.com

In the ever-evolving landscape of medical research, a quiet revolution is transforming how we approach clinical trials. Voluntary data sharing is emerging as a powerful strategy that promises to enhance transparency of medical science, enhance research efficiency, and ultimately improve patient outcomes.

Clinical Data Sharing: Regulatory Required vs Voluntary 

Regulatory clinical data sharing, mandated by policies like EMA Policy 0070 and Health Canada PRCI, requires pharmaceutical companies to anonymize and redact clinical data in documents before public disclosure, ensuring patient privacy while promoting transparency. These regulations establish strict guidelines for data protection, submission timelines, and compliance measures, making them a non-negotiable aspect of regulatory approval processes. In contrast, voluntary clinical data-sharing initiatives led by clinical trial sponsors are driven by commitments to scientific collaboration, innovation, and trust-building. 

Unlike regulatory mandates, voluntary sharing allows sponsors greater flexibility in determining what data to share, with whom, and under what conditions. While both approaches aim to advance medical research and enhance transparency, regulatory policies impose standardized, enforceable frameworks, whereas voluntary initiatives have historically  relied on industry best practices and ethical considerations.

The Benefits of Voluntary Clinical Data Sharing & Kudos to Those Leading the Way

Voluntary clinical data sharing is a powerful force driving medical innovation, scientific collaboration, and patient trust. Unlike mandated disclosures, voluntary initiatives allow sponsors to proactively share insights, fostering transparency and accelerating the development of new treatments. By enabling independent researchers to analyze trial data, these efforts can lead to new discoveries, validate findings, and even uncover potential safety signals earlier. This open exchange strengthens public confidence in clinical research, demonstrating a commitment to ethical responsibility beyond regulatory requirements.

Kudos to the forward-thinking organizations and sponsors who embrace voluntary data sharing! Their leadership not only enhances scientific progress but also sets a gold standard for integrity and trust in the industry. By choosing to go beyond compliance and put patient-centered research first, they are shaping the future of healthcare for the better.

The Untapped Potential of Clinical Trial Data

Every clinical trial represents a significant investment of time, resources, and human participation. Traditionally, these studies were viewed as isolated research efforts, with data typically used to answer a single primary research question. However, this approach leaves tremendous potential unexplored. Each clinical trial contains a wealth of information that could provide insights far beyond its original scope.

The motivations for data sharing are multifaceted and compelling:

1. Advancing Scientific Knowledge

Individual participant-level data can be a goldmine for researchers. By making this data available, scientists can:

• Conduct comprehensive meta-analyses
• Develop more sophisticated statistical methods
• Design more targeted future clinical trials
• Explore research questions not originally anticipated in the initial study design

2. Ethical Considerations and Participant Contributions

Most clinical trial participants volunteer with a profound hope: to contribute to medical knowledge and potentially help future patients. When data remains siloed, this noble intention is only partially realized. Data sharing ensures that each participant's contribution has the maximum possible impact.

3. Research Efficiency and Innovation

Data sharing eliminates redundant research efforts. Instead of repeatedly conducting similar studies, researchers can build upon existing knowledge, accelerating scientific discovery and reducing unnecessary resource expenditure.

4. Increasing Transparency and Trust

In an era of increasing skepticism towards scientific research, data sharing represents a powerful tool for rebuilding public trust. By opening up research processes, the scientific community demonstrates commitment to accountability and transparency.

Key Considerations for Implementing a Data Sharing Program

Organizations looking to develop robust data sharing initiatives should consider:

Policy Development

• Clearly define which studies will be shared
• Establish transparent criteria for data access
• Identify potential exceptions (e.g., language barriers, anonymization challenges)

Data Package Components

A comprehensive data sharing package typically includes:

• Final study protocol with amendments
• Detailed data dictionary
• Statistical analysis plan
• Clinical study report summary
• Anonymized individual patient-level data
• Anonymization report

Practical Challenges and Solutions

While data sharing offers immense potential, it's not without challenges:

• Protecting patient privacy
• Managing complex legal agreements
• Ensuring data quality and consistency
• Developing robust technological infrastructure

Sharing platforms like Vivli and solution providers like Real Life Sciences have emerged to address these challenges, together they provide an end-to-end solution for clinical trial sponsors looking to share their data. 

The Broader Impact

Voluntary data sharing is more than a technical process—it's a cultural shift in medical research. By embracing this approach, we:

• Maximize the value of every research dollar
• Respect and maximize clinical trial participants' contributions
• Accelerate medical innovation
• Build public confidence in scientific research

Looking Ahead

As technology advances and collaborative research models become more sophisticated, data sharing will become the norm rather than the exception. Emerging technologies like advanced anonymization techniques and secure data platforms will continue to lower barriers to meaningful data exchange. The power of voluntary data sharing extends far beyond individual studies. It represents a fundamental reimagining of how medical research can create value—not just for individual researchers or institutions, but for global health and human understanding.

By breaking down silos, promoting transparency, and treating each clinical trial participant's contribution with the utmost respect, we can unlock unprecedented potential in medical research. The future of clinical trials is collaborative, transparent, and driven by a shared commitment to advancing human health. To learn more about technologies to safely share data, visit rlsciences.com

In the ever-evolving landscape of clinical research, the need for transparency and data sharing has become paramount. As regulatory bodies like Health Canada and the European Medicines Agency (EMA) continue to emphasize the disclosure of clinical trial data through regulation and policy, sponsors are faced with the critical challenge of anonymizing information while preserving its utility. This delicate balance is at the heart of any research team’s decision process  between qualitative and quantitative approaches to data anonymization.

The Limitations of Qualitative Anonymization

Traditionally, the qualitative approach has been the go-to method for clinical trial data transparency. This approach  relies on the application of static and subjective rules to redact personal data found within  documents such as Clinical Study Reports (CSRs), Protocols and Statistical Analysis Plans. Although this method appears straightforward, it may not fully meet the increasing demands for transparency and data utility and the risk of re-identification of participant data is unknown and not measurable.

The qualitative approach is inherently subjective, with decisions made based on the contextual review and judgment of the individuals involved. This can lead to inconsistencies and a lack of measurable outcomes, making it challenging to satisfy the requirements of regulatory bodies. Moreover, the heavy reliance on redaction in the qualitative methodology can result in significant information loss, limiting the value and usability of the anonymized data.

The Rise of Quantitative Anonymization

In contrast, the quantitative approach to clinical trial data anonymization offers a more sophisticated and data-driven solution. This empirical methodology leverages statistical analysis and privacy models to anonymize data while preserving as much utility as possible.

At the heart of the quantitative approach is the definition of a risk threshold, which serves as a measurable target of acceptable risk of re-identification for the anonymization process. By applying privacy models like k-anonymity, the quantitative method groups participants based on similar characteristics, ensuring any one individual is not distinguishable from others within a dataset.

The advantages of this approach are manifold. Firstly, the quantitative methodology provides a clear and measurable risk of re-identification, a crucial requirement for health authorities that are increasingly favoring this more empirical approach. This level of transparency and accountability resonates with regulatory bodies and demonstrates the sponsor's commitment to patient privacy. 

Secondly, the quantitative approach aims to strike a delicate balance between data utility and privacy protection. By leveraging advanced anonymization techniques, such as pseudonymization, generalization, and categorical suppression, the quantitative method can transform the data in a way that preserves its analytical value while still safeguarding individual confidentiality.

Managers within clinical trial sponsors prefer the quantitative methodology due to its empirical and measurable benefits.

The 6-Step Quantitative Anonymization Process

1. Defining the Privacy Model and Risk Threshold: The first step involves establishing the framework for the anonymization, including the selection of a privacy model (e.g., k-anonymity) and the definition of a risk threshold (e.g., 9% risk of re-identification).
2. Determining the Reference Population: Sponsors must decide whether to use the study population or a larger, similar reference population to enhance the anonymization process. The reference population can help reduce the equivalence class size, allowing for more granular data transformations while still adhering to the risk threshold.
3. Applying Anonymization Techniques: The quantitative approach tailors the anonymization techniques to the specific data types. This may include pseudonymizing subject IDs, generalizing age into hierarchical bands, and applying categorical suppression for variables like country.
4. Evaluating Anonymization Rules and Data Utility: The sponsor must prioritize the preservation of data utility while ensuring that the anonymization rules adhere to the defined risk threshold. This may involve filtering anonymization options based on information loss or applying suppression limits to balance data utility and privacy protection.
5. Analyzing Adverse Events: Adverse events are a critical component of clinical trials, and the quantitative approach recognizes their importance. A specialized process should be implemented to ensure the retention of clinically relevant adverse events, even if they do not meet the strict statistical criteria.
6. Assessing Final Residual Risk: The final step involves analyzing the total residual risk and ensuring that the results meet the required metrics for the anonymization report. This comprehensive assessment provides a clear understanding of the remaining risk, allowing sponsors to make informed decisions and satisfy regulatory requirements.

The Role of Technology and Automation

A key advantage of the quantitative approach is its reliance on technology and automation. Rather than manually applying redaction rules, sponsors can leverage specialized software like RLS Protect to perform the complex statistical analysis, configure anonymization scenarios, apply the anonymization techniques throughout the clinical documents and generate the required anonymization reports as expected by the health authority 

This level of automation not only streamlines the process but also enhances its repeatability and scalability - crucial considerations as sponsors navigate an increasing number of transparency-related projects in support of their R&D pipelines. By offloading the heavy lifting of data transformation and risk assessment to specialized and purpose-built software, sponsors can focus on the strategic aspects of the anonymization process, ensuring that the final results meet regulatory requirements while preserving the maximum possible data utility all while providing the opportunity for their internal teams to focus on critical path activities.

The integration of technology also introduces an element of consistency and objectivity that can be challenging to achieve with a purely manual, qualitative approach. The automated tools apply the defined anonymization techniques and risk thresholds systematically, reducing the potential for human error or subjective decision-making that can undermine the integrity of the anonymized data.

In today’s data-driven landscape, the demand for transparency and the exchange of clinical trial data has grown exponentially. While this shift opens doors to more robust research and collaboration, it also presents unique challenges in safeguarding the privacy and confidentiality of trial participants and commercially confidential data. Balancing the need to protect individual privacy while retaining the clinical value of shared data is critical. One approach to navigate this challenge is through data anonymization, specifically using the qualitative methodology.

In this in-depth guide, we will explore the nuances of qualitative anonymization in clinical trials, covering key principles, best practices, and critical considerations to help you apply it effectively. The goal is to help researchers strike the delicate balance between patient re-identification risks and retaining the utility of clinical trial data.

What is Qualitative Anonymization?

Before diving into the application of qualitative anonymization, it’s essential to understand what it entails. Unlike quantitative anonymization, which relies on measurable statistical analysis to ensure data anonymity and preservation of data utility, qualitative anonymization is based on a combination of a set of rules, judgment, expert knowledge, and a case-by-case review of sensitive information. This method introduces subjectivity, meaning researchers must apply a flexible and context-driven approach to protect participant data.

The goal of data anonymization is twofold:

1. To minimize the risk of participant re-identification.
2. To preserve the utility of the data for meaningful clinical insights.

The qualitative anonymization process involves defining rules for handling personally identifiable information (PII) and other sensitive data points within clinical trial documents. Given that no statistical models are used in the qualitative approach, the effectiveness largely depends on human expertise, manual review, and contextual understanding.

Key Considerations When Applying Qualitative Anonymization

A well-executed qualitative anonymization process begins with a firm understanding of several core considerations. These guiding principles ensure that data is anonymized appropriately while still retaining its clinical value. Below are the five key considerations to keep in mind:

1. Contextual Judgment

In qualitative anonymization, contextual judgment is critical. Unlike quantitative methods, which rely on automated algorithms or statistical models, qualitative anonymization involves subjectivity. This means researchers must make informed decisions on what data to anonymize, retain, or generalize based on the context of the trial.

Each clinical trial is unique. The identifiers in one study may not pose the same risks as in another. For example, a trial focused on a rare disease could make even minor personal details highly identifying, whereas the same information might pose less risk in a more common disease setting.

Researchers must ensure that the anonymization rules they apply are tailored to each trial, identifying sensitive data and making informed decisions about how to handle it. Contextual judgment helps protect participant privacy while retaining relevant data that contributes to the study’s overall integrity.

2. Manual Review

One of the hallmarks of qualitative anonymization is the reliance on manual review. While automated systems can help identify and classify personal data, the ultimate decision whether to redact or retain potentially sensitive information will always be a manual process.

Manual review is particularly important for high-focus sections of clinical trial documents, such as patient narratives, aggregate-level data, or personal contact information. These sections often contain intricate details that may inadvertently lead to re-identification if not properly anonymized. Conducting a detailed review ensures that identifiers are not overlooked and that any retained data is purposefully kept, rather than being missed.

3. Expert Knowledge Redaction

Subject matter experts (SMEs) play a crucial role in qualitative anonymization. These individuals must have a deep understanding of the clinical trial, the study design, and the data in question. Their knowledge allows them to make well-informed decisions about what data to redact, retain, or transform.

SMEs are responsible for ensuring that sensitive data points are handled correctly and that the anonymization process is both effective and compliant with regulatory guidelines. They also help identify high-priority areas that require special attention, such as adverse events or unique medical histories that might pose a higher re-identification risk.

4. Redaction vs. Transformation

A critical decision in the anonymization process is determining when to redact data and when to transform it. Redaction involves completely removing identifiable information, while transformation refers to replacing it with more generalized or abstract categories.

For example, instead of removing all geographical information, researchers might transform "United States" into the broader category of "North America." Similarly, for gender-specific trials, "Female" might be retained in the dataset for clarity.

These decisions are made based on trial-specific factors, such as whether the information has already been publicly disclosed (e.g., on ClinicalTrials.gov), if it is a single-race or single-gender study or how critical the data is for the study’s integrity. The choice between redaction and transformation has a significant impact on the balance between protecting participant privacy and preserving the utility of the data.

Further, the process of anonymizing the data is more complex than straight redaction. Purpose built software solutions may be needed to accomplish this, especially for large projects that may involve anonymization of hundreds and commonly thousands of pages of sensitive participant information.

5. Iteration and Validation

Given the subjectivity and human element involved in qualitative anonymization, it’s vital to approach the process iteratively. This means applying multiple rounds of review and validation to ensure that the anonymization rules are consistently applied and that no sensitive data has been overlooked.

Iteration allows researchers to revisit the rules they initially defined and adjust them based on findings from the manual review process. This ongoing validation ensures that anonymization is effective, while also ensuring consistency across different datasets and study documents.

Defining Anonymization Rules

Once the key considerations are understood, the next step is to define specific rules for anonymization. These rules are not static and may evolve as the trial progresses or as new data becomes available. Researchers often revisit and refine these rules periodically to ensure they remain relevant and effective.

Below is an example of how anonymization rules are applied to specific data categories:

• Participant ID: Direct identifiers like participant IDs are pseudonymized. Pseudonymization replaces a real identifier with a code, which allows for linkage across study documents without revealing the participant’s identity. This retains the utility of the data while preventing re-identification.
• Contact Details: Personal contact information is typically redacted to ensure that participants cannot be re-identified through their contact details.
• Gender: Depending on the study, gender information may either be retained (e.g., in single-gender studies) or redacted in cases where it poses a re-identification risk.
• Dates: Rather than redacting dates, suppression techniques may be used. This means replacing specific dates with more general terms like "Date," which maintains context for the reader while protecting the participant’s privacy.
• Medical History: Medical history is generally redacted unless it is directly related to the study indication or the adverse event profile. This allows for the retention of clinically relevant data while ensuring participant confidentiality.

Each research team or organization will need to decide what anonymization or redaction rules to apply.  

Anonymization of Adverse Events: A High-Priority Consideration

One of the most critical elements in qualitative anonymization is the disclosure and protection of adverse event data. Adverse event data is often prioritized by regulatory bodies, meaning that even in heavily redacted or suppressed datasets, adverse events should be disclosed wherever possible

Regulatory agencies emphasize the importance of adverse event retention because of its impact on understanding the safety profile of a drug. However, qualitative methodologies must strike a careful balance to avoid inadvertently exposing sensitive participant information.

There are two main strategies for dealing with adverse events:

1. Selective Retention: Researchers can identify rare, sensitive and observable adverse events and review them within the context of the study. If these events are relevant to the drug’s safety profile or the trial indication, they may be retained. Otherwise, they may be anonymized or generalized to a higher-level group term.
2. Complete Retention: In certain cases, all adverse events are retained, despite the potential risk of re-identification. This approach requires careful consideration, as retaining all adverse event data is likely to increase the risk of participant re-identification.

Contextual Review in Anonymization of Adverse Events

Contextual review is a key component of qualitative anonymization, particularly when it comes to assessing adverse events. The context in which a term appears can determine whether it is retained, generalized, or redacted.

For example, in a diabetes study, an adverse event like "amputation of the left foot" may be retained because it is relevant to the disease being studied. In contrast, in a non-psychiatric trial, a term like "schizophrenia" might be generalized to "psych disorder" if it is unrelated to the study drug or trial indication.

Contextual review allows researchers to make more informed decisions about how to handle specific data points, ensuring that the data remains useful without compromising participant privacy.

Best Practices for Successful Qualitative Anonymization

To ensure the success of a qualitative anonymization strategy, the following best practices should be followed:

1. Frequent Iteration: Because qualitative anonymization is subjective, multiple rounds of review are essential. This allows researchers to revisit their rules and refine them as needed to ensure consistency and effectiveness.
2. Expert Involvement: SMEs are crucial to the success of qualitative anonymization. Their knowledge of the trial and its data ensures that anonymization is applied correctly and in compliance with regulatory requirements.
3. Balancing Redaction and Data Utility: Over-redaction can strip a dataset of its clinical value, while under-redaction can expose participants to re-identification risks. Researchers must carefully balance these competing priorities to ensure that the data remains both secure and useful.
4. Regulatory Compliance: It’s critical to adhere to regulatory guidelines when applying qualitative anonymization. This includes understanding the requirements of agencies like Health Canada, the FDA, and the European Medicines Agency (EMA), all of which have specific standards for data anonymization.

Conclusion

Qualitative anonymization offers a flexible and adaptable approach to data protection in clinical trials. While it requires more manual effort and subjective judgment than quantitative methods, its flexibility allows researchers to tailor anonymization practices to the unique characteristics of each trial, should they choose to do so.

By following best practices—such as thorough manual reviews, leveraging subject matter expertise, and applying a context-specific approach—researchers can minimize the risk of participant re-identification. The iterative nature of qualitative anonymization ensures that any sensitive information is adequately protected while allowing for adjustments and improvements in the anonymization strategy over time. This is especially important in high-stakes areas like adverse event data, where careful balance is needed between maintaining data integrity and ensuring privacy. 

Additionally, a successful qualitative anonymization process must maintain compliance with global regulatory standards, such as those set by the FDA, EMA, or Health Canada. Regular audits, validations, and updates to anonymization protocols help ensure the data remains both compliant and usable for ongoing research efforts.

Qualitative anonymization can support compliance with data protection requirements, however, it often comes with a challenge: preserving data utility while remaining within acceptable risk thresholds. This balance has been known to lead to excessive redaction. Further, understanding the true risk of re-identification is difficult if not impossible as the resulting anonymized data is not statistically assessed. Further, the information loss or resulting data utility is not analyzed which makes the value of the resulting anonymized data unknowable. Quantitative anonymization, on the other hand, results in clear and measurable criteria for achieving a defined risk threshold while providing the highest possible level of data utility. This highlights the significant differences between the two methodologies. 

Ultimately, qualitative anonymization can empower researchers to share clinical trial data, contribute to the advancement of science and protect the privacy of participants. By applying thoughtful, context-driven anonymization techniques, clinical trial data can be disseminated more widely, fostering collaboration and driving innovation in medical research without compromising individual confidentiality.

 Before selecting an anonymization approach for your clinical data, we recommend understanding the similarities and differences between qualitative and quantitative methodologies such that you can make an informed choice.  Real Life Sciences provides comprehensive services and software solutions for both qualitative and quantitative anonymization. For inquiries or to discuss potential projects, please reach out to us at inquiry@rlsciences.com.